tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Smith+Nephew Closes US$450m Integrity Orthopaedics Deal to Bolster Sports Medicine Portfolio

Story Highlights
  • Smith+Nephew has completed its acquisition of US-based Integrity Orthopaedics, developer of the Tendon Seam rotator cuff repair system.
  • The US$225m upfront deal, with up to US$225m in earn-outs, advances Smith+Nephew’s RISE strategy and its sports medicine leadership ambitions.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Smith+Nephew Closes US$450m Integrity Orthopaedics Deal to Bolster Sports Medicine Portfolio

Claim 50% Off TipRanks Premium

Smith & Nephew Snats ( (SNN) ) has issued an update.

On 21 January 2026, Smith+Nephew announced it had completed the acquisition of US-based Integrity Orthopaedics, an early-stage commercial developer of Tendon Seam™, a rotator cuff repair system designed to reduce re-tear rates and improve patient outcomes. The deal, structured as an initial cash payment of US$225 million with up to a further US$225 million in performance-based payments over the next five years, is positioned as a key step in executing the group’s RISE strategy to accelerate growth via strategic investments and strengthen its ambition to become the global leader in Sports Medicine, signaling an expansion of its sports medicine portfolio and a deeper push into innovative shoulder repair technologies.

The most recent analyst rating on (SNN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Neutral.

Smith & Nephew Snats’ strong financial performance and positive earnings call are the main drivers of its stock score. However, bearish technical indicators and a high P/E ratio temper the overall outlook. The company’s strategic initiatives, such as the share buyback, reflect confidence in its financial health, but challenges in emerging markets and tariff impacts pose risks.

To see Spark’s full report on SNN stock, click here.

More about Smith & Nephew Snats

Smith+Nephew is a global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue, operating through Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management business units. Founded in 1856 in Hull, UK, it now employs around 17,000 people, operates in more than 100 countries, generated $5.8 billion in sales in 2024, and is a constituent of the FTSE 100 with shares listed in London and New York.

Average Trading Volume: 651,721

Technical Sentiment Signal: Buy

Current Market Cap: $13.82B

See more data about SNN stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1